ANTIBODY SPECIFICALLY BINDING TO RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN, AND USE THEREOF

WIPO Patent Application WO/2022/114426

A1

The present invention relates to an antibody specifically binding to a receptor-binding domain (RBD) of a SARS-CoV-2 spike protein, and a use thereof. More specifically, the present invention relates to: an antibody specifically binding to a receptor-binding domain of a SARS-CoV-2 spike protein, or an antigen-binding fragment thereof; a composition for diagnosing SARS-CoV-2 infection, comprising the antibody or antigen-binding fragment thereof; a kit for diagnosing SARS-CoV-2 infection; a pharmaceutical composition for preventing or treating SARS-CoV-2 infection; an information providing method for diagnosing SARS-CoV-2 infection, using the antibody or antigen-binding fragment thereof; a polynucleotide encoding the antibody or antigen-binding fragment thereof; a vector comprising the polynucleotide; and a cell transformed with the vector. The antibody or antigen-binding fragment thereof of the present invention can bind to a receptor-binding domain of a SARS-CoV-2 spike protein to efficiently inhibit binding between the SARS-CoV-2 spike protein and an ACE2 receptor of a host cell, and thus is useful in the diagnosis, prevention, and treatment of SARS-CoV-2 infection, and can also specifically bind to RBD variants, and thus is also effective against such variants. Therefore, if the composition, kit, and information providing method of the present invention are used, SARS-CoV-2 infection can be effectively diagnosed, prevented, or treated. In addition, if the polynucleotide, vector and cell of the present invention are used, the antibody or antigen-binding fragment thereof of the present invention, which is capable of exhibiting excellent effects, can be easily produced.

KIM DAE YOUNG (KR)
KIM YU JUNG (KR)

PCT/KR2021/007607

June 02, 2022

June 17, 2021

Click for automatic bibliography generation  

OSONG MEDICAL INNOVATION FOUND (KR)

A61K39/00; C07K16/10; A61P31/14; G01N33/569

KR101969696B1	2019-04-16
KR102233689B1	2021-03-30

MASAUD SHAH, AHMAD BILAL, CHOI SANGDUN, WOO HYUN GOO: "Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization", COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, vol. 18, 12 November 2020 (2020-11-12), Sweden , pages 3402 - 3414, XP055769213, ISSN: 2001-0370, DOI: 10.1016/j.csbj.2020.11.002
KIM SANG IL, NOH JINSUNG, KIM SUJEONG, CHOI YOUNGGEUN, YOO DUCK KYUN, LEE YONGHEE, LEE HYUNHO, JUNG JONGTAK, KANG CHANG KYUNG, SON: "Stereotypic Neutralizing V H Clonotypes Against SARS-CoV-2 RBD in COVID-19 Patients and the Healthy Population", BIORXIV, 2 July 2020 (2020-07-02), pages 1 - 56, XP055899840, DOI: 10.1101/2020.06.26.174557
WALTER JUSTIN D, HUTTER CEDRIC A.J., ZIMMERMANN IWAN, WYSS MARIANNE, EGLOFF PASCAL, SORGENFREI MICHÈLE, HÜRLIMANN LEA M, GONDA IMR: "Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain.", BIORXIV, 16 May 2020 (2020-05-16), pages 1 - 18, XP055915777, DOI: 10.1101/2020.04.16.045419
DATABASE Protein 1 July 2020 (2020-07-01), ANONYMOUS: "anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]", XP055934338, retrieved from Genbank Database accession no. QKY76491

KIM, Min-tae (KR)

View/Download PDF      PDF Help

Previous Patent: USER-CUSTOMIZED SPINE ACUPRESSURE BED, AND APPARATUS AND METHOD FOR MANIPULATING SAME

Next Patent: TOUCH SENSING CIRCUIT AND TOUCH SENSOR COMPRISING SAME